Management of AIDS-related non-Hodgkin's lymphomas

Drugs

Volumn 61, Issue 9, 2001, Pages 1301-1315

  Kersten, Marie Jose ^a   Van Oers, Rien H J ^b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; MITOGUAZONE; MONOCLONAL ANTIBODY; VINCRISTINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPSTEIN BARR VIRUS; GENETIC LINKAGE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INCIDENCE; INFECTION PREVENTION; ONCOGENE; PATHOGENESIS; PROGNOSIS; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; PROGNOSIS;

HUMAN HERPESVIRUS 4;

EID: 0034886236     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161090-00006     Document Type: Review

References (96)

1. Malignant lymphomas in transplantation patients
2. Occurrence of malignancy in immunodeficiency diseases: A literature review
3. Diffuse, undifferentiated non-Hodgkin's lymphoma among homosexual males. United States
4. Revision of the case definition of acquired imunodeficiency syndrome for national reporting: United States
5. AIDS associated non-Hodgkin's lymphoma in Italy: Intravenous drug users versus homosexual men
6. Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia
7. AIDS-associated non-Hodgkin's lymphoma
8. Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS
9. The spectrum of acquired immunodeficiency syndrome-associated malignancies in San Francisco, 1980-1987
10. Chemokine and chemokine receptor gene variants and risk of NHL in HIV-infected individuals
11. Development of non-Hodgkin's lymphoma in a cohort of patients with severe HIV infection on longterm antiretroviral therapy
12. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons
13. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants
14. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1
15. A clinicopathologic study of lymphoid neoplasms associated with human immunodeficiency virus infection in Italy
16. Multicentric Castleman's disease in HIV-infection: A clinical and pathological study of 20 patients
17. Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome
18. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York University Medical Center experience with 105 patients (1981-1986)
19. AIDS-associated non-Hodgkin's lymphoma in San Francisco
20. HIV-associated lymphoma: Histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features
21. Primary central nervous system lymphoma in patients with AIDS
22. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma
23. FDG-PET in differentiating lymphoma from non-malignant CNS lesions in patients with AIDS
24. Value of combined approach with Thallium-201 single photon emission computed tomography and EBV DNA polymerase chain reaction in the cerebrospinal fluid for the diagnosis of AIDS-related primary CNS lymphoma
25. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas
26. Plasmablastic lymphomas of the oral cavity: A new entity associated with HIV-infection
27. Survival of AIDS patients according to type of AIDS-defining event
28. Human Immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival
29. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hogdkin's lymphoma: Analysis of AIDS Clinical trials group protocol 142: Low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor
30. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients
31. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with HIV-related systemic non-Hodgkin's lymphoma
32. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases
33. Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and tumors
34. Hodgkin's disease in 35 patients with HIV infection: An experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF
35. Multiple monoclonal B cell expansions and c-myc rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders: Implications for lymphomagenesis
36. Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathological heterogeneity
37. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma
38. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy
39. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders
40. EBV-specific T cell responses in HIV-1 infection: Different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma
41. Direct polyclonal activation of human B lymphocytes by the acquired immunodeficiency virus
42. Two AIDS-associated Burtkitt's lymphomas produce specific anti-i IgM cold agglutinins utilizing somatically mutated VH4-21 segments
43. Immunopathogenic mechanisms of HIV infection
44. Induction of Interleukin 6 during human immunodeficiency virus infection
45. Interleukin-6 production in high-grade B lymphomas: Correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients
46. Human B-cell interleukin-10: B cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10
47. Interleukin-10 pretreatment protects target cells from tumor- and allospecific cytotoxic T cells and downregulates class 1 expression
48. IL10 is an autocrine growth factor for AIDS-related B cell lymphoma
49. Cellular immunological responses to the virus infection
50. Epstein-Barr virus transforming proteins
51. Transactivation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr virus nuclear antigen 1
52. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma
53. In situ demonstration of Epstein-Barr virus small RNA's (EBER 1) in Acquired Immunodeficiency Syndrome related lymphomas: Correlation with tumor morphology and primary site
54. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome associated lymphoma
55. Human Immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression
56. Localization of Epstein-barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development
57. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
58. HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B cell lymphoma
59. Differential expression of bcl-6, CD138 and EBV-encoded latent membrane protein 1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas
60. Frequent mutation of the 5′ noncoding region of the bcl-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma
61. TCLI oncogene expression in AIDS-related lymphomas and lymphoid tissues
62. In vitro establishment of AIDS-related lymphoma cell lines: Phenotypic characterization, oncogene and tumour suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection
63. Deletions involving two distinct regions of 6q in B cell non-Hodgkin's lymphoma
64. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy
65. Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma
66. T-cell control of Epstein-Barr virus-infected B-cells is lost during P. falciparum malaria
67. AIDS-related malignant lymphoma: Results of prospective treatment trials
68. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial
69. Clinical and virologic effects of recombinant human granulocyte-macrophage colony stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial
70. Treatment of AIDS-related non-Hodgkin's lymphoma with a twelve week chemotherapy program
71. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma
72. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma
73. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy
74. Phase I trial of m-BACOD and granulocyte-macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma
75. Infusional cyclophosphamide, doxorubicin and etoposide in Human immunodeficiency virus-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen
76. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with Acquired immunodeficiency syndrome-related lympoma. Effect on human immunodeficiency virus and serum interleukin 6 levels over time
77. Treatment of acquired immunodeficiency syndrome-related lymphoma with a standard chemotherapy regimen
78. Dose adjusted EPOCH chemotherapy in previously untreated HIV-asssociated non-Hodgkin's lymphoma: Preliminary report of efficacy, immune reconstitution, and HIV control following therapy. 3rd National AIDS Malignancy Conference: 1999 May 6-7; Bethesda (MD)
79. Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma
80. Low dose compared with standard dose mBACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
81. Treatment of HIV-related non-Hodgkin's lymphoma adapted to prognostic factors. 3rd National AIDS Malignancy Conference: 1999; Bethesda (MD)
82. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin's lymphoma
83. High-dose therapy and autologous stem cell transplantation for HIV-1 associated lymphoma
84. Syngeneic stem cell transplantation for HIV-related lymphoma
85. Cytokines alter production of HIV-1 from primary mononuclear phagocytes
86. Treatment of patients with AIDS-related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF: Clinical outcome and effects on HIV-1 viral load
87. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multicenter phase II trial
88. Rituximab chimeric anti-CD20 monoclonai antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
89. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide (CDE) plus the anti-CD20 monoclonal antibody rituximab in HIV-associated non-Hodgkin's lymphoma (NHL)
90. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma
91. Chemotherapy for HIV-associated non-Hodgkin lymphoma in combination with highly active antiretroviral therapy is not associated with excessive toxicity. 3rd National AIDS Malignancy Conference: 1999; Bethesda (MD)
92. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus associated non-Hodgkin's lymphoma
93. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy
94. Additional experience with empiric radiotherapy for presumed human immunodeficiency vires-associated primary central nervous system lymphoma
95. AIDS-related central nervous system lymphomas
96. Involved-field radiotherapy and intra-Ommaya methotrexate/cytarabine in patients with AIDS-related lymphomatous meningitis